HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study.

AbstractAIMS:
Troponin elevation is common in acute heart failure (AHF) and may be useful for prognostication; however, available data are mixed and many previous studies used older, less sensitive assays. We examined the association between serial measurements of high-sensitivity cardiac troponin T (hs-cTnT) and outcomes in RELAX-AHF.
METHODS AND RESULTS:
Hs-cTnT was measured at baseline and days 2, 5, and 14. We assessed the relationship between baseline, peak and peak change hs-cTnT with dyspnoea relief by visual analogue scale, cardiovascular death, or HF/renal hospitalization to 60 days and cardiovascular mortality to 180 days. Models were adjusted for clinical variables and treatment assignment. Whether baseline troponin status affected the treatment effect of serelaxin was assessed using interactions terms. In 1074 patients, the median baseline troponin was 0.033 µg/L, and 90% of patients were above the 99th upper reference limit (URL). Patients with hs-cTnT >median were more likely to be men with ischaemic heart disease, worse renal function, and higher N-terminal pro-brain natriuretic peptide. Higher baseline or peak hs-cTnT and greater peak change were associated with worse outcomes independent of adjustment for covariates, but relationships were generally strongest for 180-day cardiovascular mortality (hazard ratio per doubling of baseline hs-cTnT = 1.36, 95% confidence interval 1.15-1.60). Troponin was most strongly associated with death from heart failure or from other cardiovascular causes. The treatment effect of serelaxin did not differ by baseline troponin levels.
CONCLUSION:
Hs-cTnT was elevated above the 99% URL in the majority of AHF patients. Baseline, peak, and peak change hs-cTnT were associated with worse outcomes, with the strongest relationship with 180-day cardiovascular mortality.
AuthorsG Michael Felker, Robert J Mentz, John R Teerlink, Adriaan A Voors, Peter S Pang, Piotr Ponikowski, Barry H Greenberg, Gerasimos Filippatos, Beth A Davison, Gad Cotter, Margaret F Prescott, Tsushung A Hua, Sara Lopez-Pintado, Thomas Severin, Marco Metra
JournalEuropean journal of heart failure (Eur J Heart Fail) Vol. 17 Issue 12 Pg. 1262-70 (Dec 2015) ISSN: 1879-0844 [Electronic] England
PMID26333655 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2015 The Authors European Journal of Heart Failure © 2015 European Society of Cardiology.
Chemical References
  • Recombinant Proteins
  • Troponin T
  • serelaxin protein, human
  • Relaxin
Topics
  • Acute Disease
  • Aged
  • Double-Blind Method
  • Female
  • Heart Failure (blood, drug therapy, mortality)
  • Humans
  • Male
  • Recombinant Proteins
  • Relaxin (therapeutic use)
  • Treatment Outcome
  • Troponin T (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: